217 related articles for article (PubMed ID: 21122466)
1. Investigation of carbachol and PACAP38 in a human model of migraine.
Schytz HW
Dan Med Bull; 2010 Dec; 57(12):B4223. PubMed ID: 21122466
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38.
Amin FM; Hougaard A; Schytz HW; Asghar MS; Lundholm E; Parvaiz AI; de Koning PJ; Andersen MR; Larsson HB; Fahrenkrug J; Olesen J; Ashina M
Brain; 2014 Mar; 137(Pt 3):779-94. PubMed ID: 24501094
[TBL] [Abstract][Full Text] [Related]
3. The role of genetics on migraine induction triggered by CGRP and PACAP38.
Guo S
Dan Med J; 2017 Mar; 64(3):. PubMed ID: 28260603
[TBL] [Abstract][Full Text] [Related]
4. PACAP38 induces migraine-like attacks in patients with migraine without aura.
Schytz HW; Birk S; Wienecke T; Kruuse C; Olesen J; Ashina M
Brain; 2009 Jan; 132(Pt 1):16-25. PubMed ID: 19052139
[TBL] [Abstract][Full Text] [Related]
5. Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38.
Baun M; Pedersen MH; Olesen J; Jansen-Olesen I
Cephalalgia; 2012 Mar; 32(4):337-45. PubMed ID: 22421901
[TBL] [Abstract][Full Text] [Related]
6. Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients.
Guo S; Vollesen AL; Hansen YB; Frandsen E; Andersen MR; Amin FM; Fahrenkrug J; Olesen J; Ashina M
Cephalalgia; 2017 Feb; 37(2):136-147. PubMed ID: 26994298
[TBL] [Abstract][Full Text] [Related]
7. The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study.
Rasmussen NB; Deligianni C; Christensen CE; Karlsson WK; Al-Khazali HM; Van de Casteele T; Granhall C; Amin FM; Ashina M
J Headache Pain; 2023 May; 24(1):60. PubMed ID: 37231350
[TBL] [Abstract][Full Text] [Related]
8. The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster headache.
Vollesen ALH; Snoer A; Chaudhry B; Petersen AS; Hagedorn A; Hoffmann J; Jensen RH; Ashina M
Cephalalgia; 2020 Nov; 40(13):1474-1488. PubMed ID: 32962406
[TBL] [Abstract][Full Text] [Related]
9. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
10. PACAP38 and PAC
Rubio-Beltrán E; Correnti E; Deen M; Kamm K; Kelderman T; Papetti L; Vigneri S; MaassenVanDenBrink A; Edvinsson L;
J Headache Pain; 2018 Aug; 19(1):64. PubMed ID: 30088106
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous nociception and neurogenic inflammation evoked by PACAP38 and VIP.
Schytz HW; Holst H; Arendt-Nielsen L; Olesen J; Ashina M
J Headache Pain; 2010 Aug; 11(4):309-16. PubMed ID: 20454993
[TBL] [Abstract][Full Text] [Related]
12. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion.
Csati A; Tajti J; Kuris A; Tuka B; Edvinsson L; Warfvinge K
Neuroscience; 2012 Jan; 202():158-68. PubMed ID: 22108610
[TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine.
Rahmann A; Wienecke T; Hansen JM; Fahrenkrug J; Olesen J; Ashina M
Cephalalgia; 2008 Mar; 28(3):226-36. PubMed ID: 18254893
[TBL] [Abstract][Full Text] [Related]
14. PACAP38 dose-response pilot study in migraine patients.
Vollesen AL; Guo S; Ashina M
Cephalalgia; 2017 Apr; 37(4):391-395. PubMed ID: 27084887
[TBL] [Abstract][Full Text] [Related]
15. PACAP38 in human models of primary headaches.
Ashina H; Guo S; Vollesen ALH; Ashina M
J Headache Pain; 2017 Nov; 18(1):110. PubMed ID: 29453754
[TBL] [Abstract][Full Text] [Related]
16. Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine.
Vollesen ALH; Amin FM; Ashina M
Neurotherapeutics; 2018 Apr; 15(2):371-376. PubMed ID: 29464574
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat.
Baun M; Hay-Schmidt A; Edvinsson L; Olesen J; Jansen-Olesen I
Eur J Pharmacol; 2011 Nov; 670(1):186-94. PubMed ID: 21914446
[TBL] [Abstract][Full Text] [Related]
18. Change in brain network connectivity during PACAP38-induced migraine attacks: A resting-state functional MRI study.
Amin FM; Hougaard A; Magon S; Asghar MS; Ahmad NN; Rostrup E; Sprenger T; Ashina M
Neurology; 2016 Jan; 86(2):180-7. PubMed ID: 26674334
[TBL] [Abstract][Full Text] [Related]
19. Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine.
Guo S; Vollesen AL; Hansen RD; Esserlind AL; Amin FM; Christensen AF; Olesen J; Ashina M
Cephalalgia; 2017 Feb; 37(2):125-135. PubMed ID: 26994299
[TBL] [Abstract][Full Text] [Related]
20. Effect of the H
Vollesen LH; Guo S; Andersen MR; Ashina M
Cephalalgia; 2019 Apr; 39(5):597-607. PubMed ID: 30165750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
